Lilly’s Zepbound Cut Risk of Diabetes by 94% in Obese People

Madison Muller, a Bloomberg News Health Care Reporter, dives into groundbreaking research revealing that Eli Lilly's ZEP Bound can reduce diabetes risk by 94% in obese patients over three years. She discusses the significant long-term health benefits of weight-loss drugs and their role in battling chronic diseases like type 2 diabetes. The conversation also covers the shift from injections to pills in drug delivery and the fierce competition among pharmaceutical firms driving these innovations.